HERZLIYA, Israel and CALGARY, AB, Aug. 27, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies is pleased to announce its...
Related Questions
Did the update include any new milestones or partnerships for the drug delivery platform that could affect growth forecasts?
How did the half‑year revenue and net loss compare to analysts' expectations?
What revisions, if any, were provided to the company's 2025 cash‑runway and future financing plans?